Indian Generic Drug Company Secures $85M Investment

India's E-Pharmacy Landscape and Truemeds' Unique Approach

India represents a substantial market for pharmaceuticals, supporting over 400 million individuals with chronic health conditions. While numerous e-pharmacies prioritize rapid delivery, genuine affordability continues to be the primary concern for many patients. Truemeds has adopted a distinct strategy, focusing on guiding patients toward more cost-effective medication alternatives. This approach is now yielding positive results, evidenced by recent funding at a valuation roughly four times greater than its previous assessment.

Recent Funding and Valuation Growth

The startup, established six years ago, has secured $85 million in a new funding round. This includes $65 million in primary capital and $20 million in secondary funding, spearheaded by Accel, with contributions from Peak XV Partners. Reports from TechCrunch initially highlighted Accel’s discussions regarding investment in Truemeds last year. WestBridge Capital and InfoEdge Ventures, existing investors, also participated in this round.

This latest investment has propelled Truemeds’ valuation to exceed $400 million, a significant increase from the $110 million valuation recorded in its previous funding round two years prior.

Differentiating from Competitors

Truemeds was founded in 2019, entering a competitive Indian online pharmacy market already populated by major companies offering substantial discounts on branded generic medications. However, several of these companies encountered difficulties sustaining their initial growth. PharmEasy, backed by Prosus Ventures, for example, experienced a valuation decline from a peak of $5.6 billion to below $600 million, while 1mg was acquired by Tata Digital, a part of the Tata Group.

Rather than directly competing, Truemeds’ founders strategically chose to concentrate on a specialized segment: generic medicines.

Focus on Affordability and Patient Education

“A key obstacle is informing consumers about more affordable options when they are struggling to afford their current medications,” explained Truemeds co-founder Akshat Nayyar. “We identified a gap in the market where no one was actively working to address this issue, and we aimed to bridge it.”

The Mumbai-based company provides recommendations for generic alternatives to consumers who require branded medications. This ultimately leads to cost savings, as generic drugs are typically less expensive than their branded counterparts due to efficiencies in their development.

Revenue Growth and Customer Base

Truemeds reports that its unique strategy has proven successful, with revenue increasing by over 66% year-over-year to ₹5 billion ($57 million) in the last fiscal year. The company boasts a customer retention rate of over 50% after 12 months and currently serves an average of 500,000 customers monthly, totaling 3 million customers to date.

Furthermore, Truemeds now reaches over 20,000 postal codes nationwide, with more than 75% of its customer base originating from tier-2 cities and smaller locations.

Challenges in Promoting Generic Medication Adoption

Despite these successes, a significant challenge remains: educating customers about alternatives to their prescribed medications and persuading them to switch from branded drugs to generics.

“Patients often become accustomed to the price of their prescribed brand, and a sudden reduction in price raises questions about the reason for the lower cost,” Nayyar stated.

Key Takeaways

India’s pharmaceutical market is vast, with a significant need for affordable medication.
Truemeds differentiates itself by focusing on generic medicine alternatives.
The company has experienced substantial growth in revenue and customer base.
Educating patients about the benefits of generics remains a crucial challenge.

A Shift Towards Discounts in the E-Pharmacy Landscape

Currently, many online pharmacies prioritize rapid delivery, a departure from the initial strategies employed within the industry. Previously, Indian e-pharmacies commonly utilized discounts of up to 25% to incentivize customer acquisition.

However, according to Nayyar, these discounts diminished to 20%, and subsequently to 15% – the present average – as companies focused on customer acquisition through rapid delivery services and expended capital resources.

Truemeds is adopting a contrasting approach, having increased its average discount rate from 29% to 32% over the past year. The company reports that customers who switch brands on their platform can achieve savings of up to 47% on their medications.

Leveraging Procurement and Technology

These enhanced discounts are a result of Truemeds’ robust procurement network with pharmaceutical companies. The startup utilizes its technological capabilities to provide manufacturers with improved demand forecasting.

This enhanced visibility allows for more efficient production planning in subsequent quarters. It optimizes the supply chain and ultimately contributes to cost savings.

Furthermore, Truemeds manages its own logistics operations in key metropolitan areas and collaborates with cost-effective logistics providers for broader coverage.

Prioritizing Savings Over Speed

“From the viewpoint of a patient managing a chronic condition, our four-hour delivery timeframe is adequate,” Nayyar stated. This allows for more predictable purchasing patterns.

Truemeds aims to maximize efficiency and transfer increased discounts to consumers, rather than solely concentrating on achieving the quickest possible delivery times.

The company believes that prioritizing cost savings offers a more sustainable and beneficial model for patients in the long run.

Advancing Healthcare with AI and Diagnostic Services

To effectively encourage patients to select generic medications over their branded counterparts, Truemeds prioritizes comprehensive consultations. Currently, the company facilitates approximately 10-12 million consultations annually.

Over time, Truemeds has engineered an algorithm capable of analyzing numerous factors to recommend suitable alternatives to requested branded drugs. This system accounts for details like sugar coating, suitability for pediatric patients, manufacturing location, and GMP certification of the production facility.

A chatbot is also available to provide rapid responses to common user inquiries.

Future Developments and Expansion Plans

The company’s future strategy includes the development of an AI-driven system designed to personalize interactions based on customer behavior and their history with generic medication options.

Furthermore, Truemeds is establishing a new office in Bengaluru and is committing at least 20% of its capital towards engineering and product innovation.

The company is also exploring expansion into the diagnostics sector through collaborations with established national pathology laboratories.

Pilot programs for lab testing services are planned for select tier-2 cities within the coming three to four months.

Commitment to Affordability and Growth

The co-founder emphasized that the core objective remains making healthcare accessible and affordable for all patients. Having successfully established its model with pharmaceuticals, Truemeds intends to scale its operations.

Concurrently, the company is investigating opportunities to replicate this success within the diagnostics market, aiming to become the lowest-cost provider for frequently requested tests.

Over the next year, Truemeds plans to increase the number of its fulfillment centers by 300%, expanding from the current 19 locations to strengthen its market presence.

Prior to this funding round, Truemeds had secured $50 million and retains 30-35% of those funds.